Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Sector news Pharmaceuticals - NEC
11:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
07:38aRoche to Appoint James Sabry as Head of Partnering
DJ
06/21LONDON MARKETS: FTSE 100 Drops As Oil Shares Extend Losses; Pound Rallies On ..
DJ
06/21Canada sets October start for legal recreational marijuana sales
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
06/20SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/20Merck KGaA Partners With Alibaba Health in China
DJ
06/19High Times refreshes IPO plans as cannabis companies build buzz on Wall Stree..
RE
06/19MERCK : to Distribute HistoCyte Laboratories Products
DJ
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19Roche to Pay $2.4 Billion for Full Control of Foundation Medicine -- 2nd Upda..
DJ
06/19Roche pays $2.4 billion for rest of cancer expert Foundation Medicine
RE
06/19Roche, Foundation Medicine Reach Definitive Merger Agreement -- Update
DJ
06/19SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/19Roche, Foundation Medicine Reach Definitive Merger Agreement
DJ
06/18How U.S. tax reform rewards companies that shift profit to tax havens
RE
06/18Indivior shares rise after U.S. court order blocks generic rival drug
RE
06/18INDIVIOR : Wins Legal Battle; Temporarily Blocks Launch of Generic Drug
DJ
06/18SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/16International fund managers turn to financials, tech as trade worries rise
RE
06/15BAYER : Japan suspends sale of Canadian wheat after GMO wheat found in Alberta
RE
06/15UK's Indivior will fight U.S. FDA's approval for copycat drug
RE
06/15Indivior Shares Drop After U.S. Approves Suboxone Generics
DJ
06/15UK's Indivior to seek injunction after rival gets FDA approval for generics
RE
06/15NOVARTIS : Study Shows Jakavi Reduces Blood Clots, Risk of Death
DJ
06/15Roche's Gazyva Cancer Drug Outperforms MabThera
DJ
06/15NOVARTIS : Cohen Probe Is Extended to Lobbying -- WSJ
DJ
06/15SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/15NOVARTIS : Releases Phase 3 Data for Zessly, Erelzi Biosimilars
DJ
06/14ADRs End Mostly Lower; iQiyi, Unilever Trade Actively
DJ
06/14NOVARTIS : Prosecutors Investigating Michael Cohen for Possible Illegal Lobbying
DJ
06/14ABBOTT LABORATORIES : Allergan appoints former Abbott executive to its board
RE
06/14GLAXOSMITHKLINE : Positive Results for ViiV Healthcare's HIV Studies
DJ
06/14SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/14Roche to Present Ocrevus Data Showing Delayed Wheelchair Need in MS Patients
DJ
06/14FDA Rejects Mylan's Asthma Generic Over Deficiencies -- Market Mover
DJ
06/13MERCK AND : Gets FDA Priority Review for Expanded Gardasil Age Range
DJ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/13SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/12JOHNSON & JOHNSON : Accepts Platinum Equity's $2.1 Billion Offer for LifeScan Bu..
DJ
06/12Eli Lilly, AstraZeneca Drop Two Late-Stage Alzheimer's Drug Trials -- Update
DJ
06/12GSK says vaccine business president to leave by year-end
RE
06/12GLAXOSMITHKLINE : Vaccines President to Leave Company by Year-End
DJ
06/12Eli Lilly, AstraZeneca Drop Two Late-Stage Alzheimer's Drug Trials
DJ
06/12AstraZeneca, Eli Lilly to Stop Alzheimer's Treatment Trials
DJ
06/12SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/11Investors ready to resuscitate Johnson & Johnson's ailing stock
RE
06/11Takeda shareholder group aims to block $62 billion Shire deal
RE
1  2  3  4  5  6  7  8  9  10Next
Financials (€)
Sales 2018 35 273 M
EBIT 2018 8 334 M
Net income 2018 5 099 M
Debt 2018 15 707 M
Yield 2018 4,46%
P/E ratio 2018 16,29
P/E ratio 2019 15,22
EV / Sales 2018 2,86x
EV / Sales 2019 2,71x
Capitalization 85 320 M
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
SANOFI-4.93%99 211
JOHNSON & JOHNSON-12.27%328 751
PFIZER0.00%211 871
NOVARTIS-10.17%188 057
ROCHE HOLDING LTD.-12.19%183 625
MERCK AND COMPANY8.90%164 189
AMGEN7.07%123 203
ABBOTT LABORATORIES9.23%109 294
BAYER-5.32%104 138
GLAXOSMITHKLINE17.20%101 051
ELI LILLY AND COMPANY2.79%94 237
ASTRAZENECA5.04%89 519
BRISTOL-MYERS SQUIBB COMPANY-12.47%87 677
NOVO NORDISK A/S-13.74%85 393
ALLERGAN PLC5.79%58 675
CELGENE CORPORATION-23.88%57 580
SHIRE2.82%47 913
JIANGSU HENGRUI MEDICINE CO LTD48.77%44 755
ASTELLAS PHARMA INC21.10%31 515
TAKEDA PHARMACEUTICAL CO LTD-30.86%30 885
CHUGAI PHARMACEUTICAL CO LTD3.64%30 337